Opko Health Inc (OPK)

[terry hallinan]

Rx For the Frights - Treatment For Warts, Scars, Cancers and More

This is not about the usual targets and signposts but about RXII that those that know it all forgot about years ago.

March 7, 2013

RXi Pharmaceuticals and OPKO Health Announce Strategic Pooling of RNAi Assets

WESTBOROUGH, Mass. & MIAMI--(BUSINESS WIRE)-- RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and OPKO Health, Inc. (NYSE: OPK) today announced a strategic pooling of their respective assets in the field of RNA interference (RNAi). Therapeutics based on RNAi technologies hold great promise to treat a wide range of diseases.....

http://investor.opko.com/releasedetail.cfm?releaseid=746280

HOLD IT RIGHT THERE!

That RNAi keyword among all the scientific mumbo-jumbo for non-scientists should have been a HUGE WARNING because we are now into antisense that has failed for over half a century despite two Nobel prizes and untold billions thrown into a black hole by academics and otherwise sensible people alike since it was invented by Prof. James Summerton from reading a scientific Siberian journal during the height of the Cold War.

The wildman professor in Oregon [natch] later blamed his loosing of the demon antisense on the world on the three Siberian temptresses writing in the dark, frozen Siberian vastness but they naturally declined the dubious honor.

But danged if there isn't something arising out of that primeval ooze called antisense among all its other disguises.

And one of those is RXi Pharmaceuticals, the wart and cancer remover, that the usual keen eye of Frost spotted very late in the game.

It hasn't been all peaches and cream. True R&D seldom is but there are signs of higher life that muckrakers like Hindenburg tend to overlook.

From the RXi Pharmaceuticals, Next Generation in RNAi, website:

RXi is developing immuno-oncology therapeutics, based on its proprietary RNAi technology platform, for significant unmet needs.

http://www.rxipharma.com/

The warts and even ophthalmology are let to licensing as RXII enters the high stakes cancer game with its advanced self-delivering RNAi that is far from the longtime sure loser of just a year or two ago.

I look forward to next Monday and all the foreseeable Mondays after with a sense of adventure and renewal for OPK rather than fear and loathing despite a lengthy struggle as nearly always with R&D.

I have never been real high on the humdrum that gets Warren Buffett's juices flowing and only he can excite.

Just my way for what little it's worth.

Best, Terry